LD Piro

996 total citations
12 papers, 821 citations indexed

About

LD Piro is a scholar working on Genetics, Immunology and Oncology. According to data from OpenAlex, LD Piro has authored 12 papers receiving a total of 821 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Genetics, 5 papers in Immunology and 4 papers in Oncology. Recurrent topics in LD Piro's work include Chronic Lymphocytic Leukemia Research (9 papers), Viral-associated cancers and disorders (3 papers) and Immune Cell Function and Interaction (3 papers). LD Piro is often cited by papers focused on Chronic Lymphocytic Leukemia Research (9 papers), Viral-associated cancers and disorders (3 papers) and Immune Cell Function and Interaction (3 papers). LD Piro collaborates with scholars based in United States. LD Piro's co-authors include Ernest Beutler, CJ Carrera, DA Carson, Alan Saven, RJ Lukes, S Poppema, Kathryn Hollenbach and BR Meisenberg and has published in prestigious journals such as Blood, Bone Marrow Transplantation and PubMed.

In The Last Decade

LD Piro

12 papers receiving 794 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
LD Piro United States	10	578	391	292	243	142	12	821
CJ Carrera United States	6	473 0.8×	305 0.8×	184 0.6×	181 0.7×	156 1.1×	7	674
DA Carson United States	13	881 1.5×	558 1.4×	426 1.5×	288 1.2×	245 1.7×	16	1.3k
Pramoda Challagundla United States	10	264 0.5×	356 0.9×	346 1.2×	223 0.9×	154 1.1×	15	742
CE Grossi Italy	16	289 0.5×	225 0.6×	418 1.4×	105 0.4×	106 0.7×	25	755
MJ Keating United States	6	452 0.8×	272 0.7×	203 0.7×	145 0.6×	132 0.9×	9	641
Marek Kasznicki Poland	11	485 0.8×	403 1.0×	182 0.6×	94 0.4×	60 0.4×	18	564
Iwona Hus Poland	18	451 0.8×	239 0.6×	710 2.4×	458 1.9×	60 0.4×	96	1.2k
Prashant Tembhare India	17	261 0.5×	244 0.6×	180 0.6×	300 1.2×	296 2.1×	97	909
Michelle Boyer United Kingdom	12	816 1.4×	626 1.6×	290 1.0×	228 0.9×	105 0.7×	33	1.1k
Anna‐Maria Fink Germany	17	886 1.5×	818 2.1×	364 1.2×	183 0.8×	45 0.3×	58	1.0k

Countries citing papers authored by LD Piro

Since Specialization

Citations

This map shows the geographic impact of LD Piro's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by LD Piro with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites LD Piro more than expected).

Fields of papers citing papers by LD Piro

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by LD Piro. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by LD Piro. The network helps show where LD Piro may publish in the future.

Co-authorship network of co-authors of LD Piro

This figure shows the co-authorship network connecting the top 25 collaborators of LD Piro. A scholar is included among the top collaborators of LD Piro based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with LD Piro. LD Piro is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

1.

Meisenberg, BR, et al.. (1998). Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplantation. 21(9). 927–932. 71 indexed citations

2.

Piro, LD. (1996). Cladribine in the treatment of low-grade non-Hodgkin's lymphoma.. PubMed. 33(1 Suppl 1). 34–9. 9 indexed citations

3.

Piro, LD, et al.. (1994). Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle. Blood. 84(10). 3457–3464. 17 indexed citations

4.

Saven, Alan, et al.. (1994). Immunomorphologic analysis of bone marrow biopsies after treatment with 2-chlorodeoxyadenosine for hairy cell leukemia. Blood. 84(12). 4310–4315. 50 indexed citations

5.

Lukes, RJ, et al.. (1993). Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 82(4). 1277–1287. 7 indexed citations

6.

Lukes, RJ, et al.. (1993). Diagnostic application of two-color flow cytometry in 161 cases of hairy cell leukemia. Blood. 82(4). 1277–1287. 139 indexed citations

7.

Piro, LD. (1993). 2-Chlorodeoxyadenosine: treatment of hairy cell leukemia, chronic lymphocytic leukemia, and lymphocytic lymphoma.. PubMed. 30(4 Suppl 6). 28–30. 1 indexed citations

8.

Piro, LD. (1992). 2-Chlorodeoxyadenosine treatment of lymphoid malignancies [editorial]. Blood. 79(4). 843–845. 18 indexed citations

9.

Saven, Alan, CJ Carrera, DA Carson, Ernest Beutler, & LD Piro. (1992). 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T- cell lymphoma. Blood. 80(3). 587–592. 86 indexed citations

10.

Saven, Alan, CJ Carrera, DA Carson, Ernest Beutler, & LD Piro. (1992). 2-Chlorodeoxyadenosine: an active agent in the treatment of cutaneous T- cell lymphoma. Blood. 80(3). 587–592. 66 indexed citations

11.

Piro, LD, CJ Carrera, Ernest Beutler, & DA Carson. (1988). 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 72(3). 1069–1073. 207 indexed citations

12.

Piro, LD, CJ Carrera, Ernest Beutler, & DA Carson. (1988). 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood. 72(3). 1069–1073. 150 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact